Pain Therapeutics (NASDAQ:PTIE)’s share price rose 5.1% on Monday . The company traded as high as $2.67 and last traded at $2.67, with a volume of 84,069 shares changing hands. The stock had previously closed at $2.54.

Separately, Zacks Investment Research upgraded Pain Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, May 31st.

The company has a 50-day moving average price of $2.40 and a 200-day moving average price of $2.19. The stock’s market cap is $122.27 million.

Pain Therapeutics (NASDAQ:PTIE) last announced its quarterly earnings data on Tuesday, July 19th. The biopharmaceutical company reported ($0.07) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.14) by $0.07. Analysts expect that Pain Therapeutics will post ($0.42) EPS for the current fiscal year.

Pain Therapeutics, Inc is a biopharmaceutical company. The Company is focused on drug development efforts on disorders of the nervous system, such as chronic pain. The Company’s lead drug candidate, REMOXY, is an abuse-deterrent, oral formulation of oxycodone (CII). The Company’s other products is FENROCK.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.